SynthesisFrontiers in endocrinology2026

The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis.

Yang Yu et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 382,897 people · 2026

Not counted

Lowered glycemic control

−89%−90% to −88%

Bigger than almost all for glycemic control

As reported

OR 0.11, 95% CI 0.10–0.12

Not counted

Lowered glycemic control

−21%−23% to −19%

Bigger than 2 in 10 for glycemic control

As reported

OR 0.79, 95% CI 0.77–0.81

Not counted

Lowered glycemic control

−31%−44% to −14%

Bigger than 3 in 10 for glycemic control

As reported

OR 0.69, 95% CI 0.56–0.86

Not counted

Raised glycemic control

+78%+66% to +91%

Bigger than 4 in 10 for glycemic control

As reported

OR 1.78, 95% CI 1.66–1.91

+1 more in the walkthrough ↓

Five numbers in the abstract

the abstract, start to end

… compared with placebo, Insulin [OR = 0.11, 95% CrI (0.1, 0.12)], Metformin [OR = 0.79, 95% CrI (0.77, 0.81)], and Pioglitazone [OR = 0.69, 95% CrI (0.56, 0.86)] all reduced the incidence of dementia compared to placebo, a higher incidence of Alzheimer's dementia[OR = 1.78, 95% CrI (1.66, 1.91)] and Vascular dementia[OR = 2.59, 95% CrI (2.33, 2.88)] with …

← favours treatmentfavours comparator →

could be chance

Glycemic control

OR 0.110.10–0.12

Glycemic control

OR 0.790.77–0.81

Glycemic control

OR 0.690.56–0.86

Glycemic control

OR 1.781.66–1.91

Glycemic control

OR 2.592.33–2.88

MetforminThiazolidinedionesInsulinGlycemic control

1 / 3

The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis.

What the trial testedas reported · 382,897 people · 2026

Lowered glycemic control

Lowered glycemic control

Lowered glycemic control

Raised glycemic control

Five numbers in the abstract

Where each one falls

Where it lands on the map

Not cited yet